Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

瑞鸣 - NMPA Drug Approval Details

Approvals/NMPA/瑞鸣

Approved

化学药品

瑞鸣

江苏恒瑞医药股份有限公司🇨🇳 National Medical Products Administration

Approval Date: May 27, 2026
Approval ID: 8nCycBZBoXD
Company: 江苏恒瑞医药股份有限公司
Type: 化学药品

Approval Details

Approval Id: 8nCycBZBoXD
Approval Number: 国药准字H20260027
Generic Name: 鲁兹诺雷钠片
Trade Name: 瑞鸣
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 2.5mg（以C₁₄H₁₁BrNNaO₂S计）
Reg Date: 2026-05-27
Company Name: 江苏恒瑞医药股份有限公司
Company Address: 连云港经济技术开发区黄河路38号
Production Company Name: 江苏恒瑞医药股份有限公司
Production Company Address: 连云港经济技术开发区黄河路38号
Company Detail Path: /organization/hengrui-pharma
Production Company Detail Path: /organization/hengrui-pharma

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

May 27, 2026

Approval ID

8nCycBZBoXD

Type

化学药品

Back to NMPA Approvals